November/December

Specialty pharmaceuticals featured prominently in the actions of the FDA in 2017.

To date, significant uncertainty surrounds the adoption of digital health tools into clinical development programs and trial protocols.

Pharmacy leaders should increase the availability of community pharmacy residencies, with a focus on specialty pharmacy practice. 

Partnerships are key between home infusion and hospitals to alleviate costs on the health system.

When approaching a plan for handling hazardous drugs, leaders of each organization need to be proactive in complying with USP regulations.

Through value-based care initiatives, payers are increasingly holding both providers and pharmaceutical manufacturers accountable for choosing the right combination of drug regimens and treatment protocols.

Legislators are moving toward a system in which manufacturers are held more accountable for drug cost increases.

With an increasing portfolio of specialty products and dollar volume, the value of these treatments must continue to be demonstrated.